Tokyo, Mar 8, 2006 (JCN) - RIKEN announced on March 7 its discovery that reveromycin A, a secondary metabolite of actinomycete, plays a role in treating osteoporosis. RIKEN and its research partners - Chubu University, Nihon Pharmaceutical University, the Tokyo Institute of Technology and Northwestern University - elucidated that reveromycin A, a secondary metabolite of Streptomyces sp. SN-593, a kind of soil actinomycete, can induce the apoptosis of osteoclast cells.
